NEW YORK, Feb. 21, 2017 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired shares of Stemline Therapeutics, Inc. (“Stemline”) (NASDAQ:STML) (1) pursuant and/or traceable to Stemline's secondary public offering on or about January 20, 2017; and/or (2) on the open market between January 6, 2017 and February 1, 2017, inclusive. You are hereby notified that Levi & Korsinsky has commenced the class action Braswell v. Stemline Therapeutics, et al. (Case No. 1:17-cv-00853) in the USDC for the Southern District of New York. Click here to view the complaint. To get more information go to:
http://www.zlk.com/pslra/stemline-therapeutics
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that during the class period the Company made materially false and/or misleading statements and/or failed to disclose that: (i) a patient had died in the BPDCN Trial from capillary leak syndrome immediately prior to the Company’s stock offering despite consistently stating that capillary leak syndrome was a potential side-effect of SL-401; and (ii) SL-401’s safety profile did not remain predictable and manageable over increasing treatment duration, drug exposure, and patient experience as represented by the Defendants.
Take Action: if you suffered a loss in Stemline Therapeutics you have until April 4, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com


Washington Post Publisher Will Lewis Steps Down After Layoffs
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Anta Sports Expands Global Footprint With Strategic Puma Stake
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 



